In This Section

Program: Wednesday, July 22

Tuesday, July 21 Thursday, July 23 Friday, July 24

Please note that this meeting will take place as an in-person event in Boston, Massachusetts and will not live-stream content for virtual participation. The meeting content will be recorded and made available as an on-demand program after the conference.

All presentations are scheduled to be live, in-person presentations at the date and time specified below unless noted otherwise. Program in progress.

*-Short talk from proffered abstract

Wednesday, July 22

Wednesday, July 22

Networking Breakfast

7-8 a.m. | Independence Ballroom West

Fireside Chat

8-8:45 a.m. | Grand Ballroom

Moderator: Andrew Berens, Leerink Partners, Boston, Massachusetts

  • 8 a.m. | Introduction
    Andrew Berens
  • 8:05 a.m. | Fireside Chat
    Richard Pazdur, Silver Spring, Maryland

Break

8:45-9 a.m. | Grand Ballroom Prefunction

Plenary Sessions 1-2

9-11 a.m.

Plenary Session 1: Drug Discovery – Pharma vs Biotech vs Academia

Grand Ballroom
Session Chair: William Pao, Revelio Therapeutics, Inc., New York, New York

  • 9:05 a.m. | Academia Perspective
    Timothy Heffernan, The University of Texas MD Anderson Cancer Center, Houston, Texas
  • 9:35 a.m. | Industry Perspective
    Lilli Petruzzelli, Genentech, Inc., South San Francisco, California
  • 10:05 a.m. | Biotech Perspective
    James Christensen, Terremoto Biosciences, South San Francisco, California
  • 10:35 a.m. | Panel Discussion

Plenary Session 2: Technologies, Biomarkers, and Advanced Diagnostics to Guide Target Discovery and Effective Anti-cancer Therapies

Constitution Ballroom A
Session Chair: Kurt A. Schalper, Yale University, New Haven, Connecticut

  • 9:05 a.m. | Advances and impact of circulating molecular biomarkers in oncology drug development
    Maximilian Diehn, Stanford University, Stanford, California
  • 9:30 a.m. | Immunogenomic determinants of response and resistance to immune checkpoint blockade
    Kellie N. Smith, Johns Hopkins University School of Medicine, Baltimore, Maryland
  • 9:55 a.m. | High dimensional spatial molecular studies to support target discovery and de-risk therapeutics in oncology
    Kurt A. Schalper
  • 10:20 a.m. | Interpretable image analysis using advanced computational models to support therapeutic decisions in oncology
    Issam El Naqa, Moffitt Cancer Center, Tampa, Florida
  • 10:45 a.m. | Panel Discussion
    Additional Discussant:
    Yu Shyr, Vanderbilt University Medical Center, Nashville, Tennessee

Break

11-11:20 a.m. | Grand Ballroom Prefunction

Drugging the Undruggable Sessions 1-3

11:20 am-12:50 p.m.

Drugging the Undruggable Session 1: Epigenetics

Grand Ballroom
Session Chair: Johnathan R. Whetstine, Fox Chase Cancer Center, Philadelphia, Pennsylvania

  • 11:25 a.m. | New inhibitors, degraders, and stabilizers of epigenetic targets and new approaches to target undruggable proteins
    Jian Jin, Icahn School of Medicine at Mount Sinai, New York, New York
  • 11:45 a.m. | Epigenetic therapies: A path to controlling extrachromosomal DNA and rearrangements
    Johnathan R. Whetstine
  • 12:05 p.m. | Scott A. Armstong, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 2: Transcription Factors

Constitution Ballroom A
Session Chair: Angela N. Koehler, Koch Institute for Integrative Cancer Research at MIT, Cambridge, Massachusetts

  • 11:25 a.m. | Proximity pharmacology and transcription factor drug discovery
    Michael A. Erb, The Scripps Research Institute, La Jolla, California
  • 11:45 a.m. | Direct targeting of the intrinsically disordered transactivation domain of androgen receptor enables transcriptome-selective pharmacology
    Marianne D. Sadar, BC Cancer Research, Vancouver, British Columbia, Canada
  • 12:05 p.m. | Indirectly targeting TFs; including EWS-FLI1 in Ewings Sarcoma
    Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:25 p.m. | Panel Discussion

Drugging the Undruggable Session 3: Synthetic Lethality Beyond DDR

Constitution Ballroom B
Session Chair: Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas

  • 11:25 a.m. | Novel synthetic lethal targets
    Mathew J. Garnett, Wellcome Sanger Institute, Cambridge, United Kingdom
  • 11:45 a.m. | Synthetic lethality opportunities for tumors with MMEJ deficiency
    Alan D. D’Andrea, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 12:05 p.m. | Clinical development of PRMT5 inhibitors in patients with MTAP loss cancers
    Kathryn C. Arbour, Memorial Sloan Kettering Cancer Center, New York, New York
  • 12:25 p.m. | Panel Discussion

Lunch on Own

12:50-3 p.m.

Meet-the-Expert Roundtables

1-2:30 p.m. | Independence Ballroom

Limited seating available for first 135 registrants.

  1. Keith T. Flaherty, Harvard Medical School, Boston, Massachusetts
  2. Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut
  3. Lillian L. Siu, Princess Margaret Cancer Centre, Toronto, Ontaria, Canada
  4. Timothy A. Yap, The University of Texas MD Anderson Cancer Center, Houston, Texas
  5. Raffaele Colombo, Zymeworks, Vancouver, BC, Canada
  6. Danette L. Daniels, Foghorn Therapeutics, Cambridge, Massachusetts
  7. Jayesh Desai, Peter MacCallum Cancer Centre, Melbourne, Australia
  8. Norbert Kraut, Boehringer Ingelheim, Vienna, Austria
  9. William Pao, Revelio Therapeutics, Inc., New York, New York
  10. Lilli Petruzzelli, Genentech, San Francisco, California
  11. Kurt A. Schalper, Yale University, New Haven, Connecticut
  12. Andrew M. Scott, Olivia Newton-John Cancer Research Institute, Heidelberg, Australia
  13. William R. Sellers, Broad Institute of MIT and Harvard, Cambridge, Massachusetts
  14. Kevan M. Shokat, University of California, San Francisco, California
  15. Paul Workman, The Institute of Cancer Research, London, United Kingdom

(Roster subject to change)

Challenges in Drug Discovery Sessions 1-3

3:15-5 p.m.

Challenges in Drug Discovery Session 1: Biology

Grand Ballroom
Session Chair: Paul Workman, The Institute of Cancer Research, London, United Kingdom

  • 3:20 p.m. | Integrated bioscience solutions to drug discovery challenges
    Paul Workman
  • 3:50 p.m. | A multi-agent AI system for accurately determining drug mechanism-of-action at scale
    Jason M. Sheltzer, Stanford University, Stanford, California
  • 4:20 p.m. | ELF3-driven epigenetic reprogramming creates ERK pathway dependency in SERD-resistant ER+ breast cancer*
    Na Zhang, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:25 p.m. | Dark kinase dependency screening reveals STK17A as a previously unrecognized targetable vulnerability in EGFR-altered glioblastoma*
    Eric Spinetti, STARX Therapeutics, Miami, Florida
  • 4:30 p.m. | Panel Discussion

Challenges in Drug Discovery Session 2: Chemistry

Constitution Ballroom A
Session Chair: Kevan Shokat, University of California, San Francisco, California

  • 3:20 p.m. | Kevan Shokat
  • 3:50 p.m. | Kyle Seamon, Revolution Medicines, Redwood City, California
  • 4:20 p.m. | Targeting the “undruggable” oncogene CCNE1 using a molecular glue degrader in CCNE1 amplified cancers*
    Nina Ilic-Widlund, Monte Rosa Therapeutics, Boston, Massachusetts
  • 4:25 p.m. | enFoldX: AI classification of AlphaFold3-derived structural ensembles enables T cell specificity prediction*
    Jonathan Levine, Memorial Sloan Kettering Cancer Center, New York, New York
  • 4:30 p.m. | Panel Discussion

Challenges in Drug Discovery Session 3: Clinical

Constitution Ballroom B
Session Chair: Puja Sapra, AstraZeneca, Gaithersburg, Maryland

  • 3:20 p.m. | Decision making under uncertainty: What actually predicts Ph3 success… and how to improve decision making in the future
    Cristian Massacesi, Bristol Myers Squibb, Princeton, New Jersey
  • 3:50 p.m. | Delivering on precision medicine: Navigating biological purity with operational and commercial realities
    Alice T. Shaw, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 4:20 p.m. | JAB-BX600, a first-in-class EGFR-directed antibody drug conjugate delivering a novel KRAS G12D inhibitor*
    Andrea Wang-Gillam, Jacobio (US) Pharmaceuticals, Burlington, Massachusetts
  • 4:25 p.m. | Patient-level prediction of trial outcomes with a calibrated pan-cancer foundation model*
    Samantha Liang, Unlearn.AI, San Francisco, California
  • 4:30 p.m. | Panel Discussion
    Additional Panelist:
    Jennifer Euting, Patient Advocate

Break

5-5:15 p.m. | Grand Ballroom Prefunction

Spotlight on Proffered Papers Session

5:15-6 pm | Grand Ballroom

Session Chair: Patricia M. LoRusso, Yale School of Medicine, New Haven, Connecticut

  • 5:20 p.m. | Discovery of a next-generation KAT6A inhibitor with an improved therapeutic index and reduced hematotoxicity risk*
    Davide D’Alia, Qubit Pharmaceuticals, Paris, France
  • 5:25 p.m. | VBC106: A first-in-class FOLR1/MSLN targeted tri-specific antibody drug conjugate (ADC) in ovarian cancer, endometrial cancer, lung adenocarcinoma and beyond*
    Jing Li, VelaVigo (Shanghai) Limited, Shanghai, China
  • 5:30 p.m. | DLL3 CAR-T and CAR-NK cell combination therapy promotes synergistic antitumor activity in small cell lung cancer*
    Alan Bers, Dana-Farber Cancer Institute, Boston, Massachusetts
  • 5:35 p.m. | Targeted degradation of cyclin T1 constrains transcription elongation and triggers tumour cell apoptosis*
    Janice Wenzheng Neng, University of Cambridge, Cambridge, United Kingdom
  • 5:40 p.m. | A first-in-class Pin1 degrader provides robust PKPD response and efficacy in PDAC models*
    Morgan O’Shea, Larkspur Biosciences, Cambridge, Massachusetts
  • 5:45 p.m. | GLIO-1 is a selective DHODH inhibitor that is effective in IDH-mutant gliomas and KDM6-mutated cancers*
    Diana Shi, Harvard Medical School, Boston, Massachusetts
  • 5:50 p.m. | CDK4/6 bifunctional degraders overcome CDK4/6i resistance in breast cancer and demonstrate antitumor efficacy in additional tumor types*
    Maechen Wang, Memorial Sloan Kettering Cancer Center, New York, New York

Poster Session A / exhibit show / Reception

6:15-8:45 p.m. | Back Bay Ballroom

Evening off / Dinner on own

8:45 p.m.